Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy

被引:19
作者
Figueroa-Casas, PR
Ettinger, B
Delgado, E
Javkin, A
Vieder, C
机构
[1] Hosp Saenz Pena, Dept Gynecol, Rosario, Argentina
[2] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2001年 / 8卷 / 06期
关键词
endometrial hyperplasia; unopposed estrogens; reversal rate; progestins;
D O I
10.1097/00042192-200111000-00006
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Objective: Endometrial hyperplasia, an entity considered a precursor to endometrial carcinoma, frequently develops in women receiving unopposed estrogens. Progestins used concomitantly with estrogens can largely prevent endometrial hyperplasia and carcinoma. However, the ability of progestins to reverse endometrial hyperplasia induced by estrogens is less well recognized. The purpose of this study was to assess the medical reversal rate of endometrial hyperplasia that develops in women receiving unopposed estrogen replacement therapy (ERT). Design: Review of recent literature (1990-2000). Results: Based on four large series, more than 90% of endometrial hyperplasia caused by ERT can be reversed by medical treatment. Discontinuation of estrogen and oral administration of 10 mg/day of medroxyprogesterone acetate continuously for 6 weeks or cyclically for 3 months (2 weeks of each month) are the two regimens most widely used. Other progestins also have been shown to be effective. Conclusions: Progestins are highly successful in reversing endometrial hyperplasia caused by ERT.
引用
收藏
页码:420 / 423
页数:4
相关论文
共 34 条
[1]
The effect of medroxyprogesterone acetate on angiogenesis in complex endometrial hyperplasia [J].
Abulafia, O ;
Triest, WE ;
Adcock, JT ;
Sherer, DM .
GYNECOLOGIC ONCOLOGY, 1999, 72 (02) :193-198
[2]
Down-regulation of Bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia [J].
Amezcua, CA ;
Zheng, WX ;
Muderspach, LI ;
Felix, JC .
GYNECOLOGIC ONCOLOGY, 1999, 73 (01) :126-136
[3]
Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women [J].
Beresford, SAA ;
Weiss, NS ;
Voigt, LF ;
McKnight, B .
LANCET, 1997, 349 (9050) :458-461
[4]
BERTONE E, 2000, J BR MENOPAUSE SOC, V6, P89
[5]
Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy [J].
Björn, I ;
Bäckström, T .
MATURITAS, 1999, 32 (02) :77-86
[6]
Estrogen with interrupted progestin HRT: a review of experimental and clinical studies [J].
Casper, RF .
MATURITAS, 2000, 34 (02) :97-108
[7]
de Lignieres B, 2000, MENOPAUSE AT THE MILLENNIUM, P288
[8]
EICHNER E, 1971, OBSTET GYNECOL, V38, P739
[9]
THE BIOLOGIC SIGNIFICANCE OF CYTOLOGIC ATYPIA IN PROGESTOGEN-TREATED ENDOMETRIAL HYPERPLASIA [J].
FERENCZY, A ;
GELFAND, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1989, 160 (01) :126-131
[10]
FERENCZY AH, 2000, MATURITAS, V37, P133